Xenetic (XBIO) Biosciences has entered into a Clinical Trial Services Agreement with PeriNess to advance the company’s development program for its systemic DNase I candidate in combination with chemotherapy and immunotherapy platforms for the treatment of pancreatic carcinoma, colorectal cancer and other locally advanced or metastatic solid tumors toward exploratory clinical studies. Under the terms of the Agreement, PeriNess will lead in the regulatory approval, operational execution and management of potential exploratory, investigator initiated studies of recombinant DNase as an adjunctive treatment in patients with pancreatic carcinoma and other locally advanced or metastatic solid tumors receiving chemotherapy and immunotherapy in Israeli medical centers.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XBIO:
- Xenetic presents preclinical data on DNase I with CAR T cells in murine model
- Xenetic reports Q3 EPS (28c) vs. (69c) last year
- Xenetic presents preclinical data on DNase platform technology
- Xenetic Biosciences Expands Collaboration for Cancer Treatment
- Xenetic extends research collaboration with Scripps Research Institute